LXEO

LXEO

USD

Lexeo Therapeutics Inc. Common Stock

$8.190-0.110 (-1.325%)

即時價格

Healthcare
生物科技
美國

價格圖表

Loading Chart...

關鍵指標

市場指標
公司基本面
交易統計

市場指標

開盤

$8.300

最高

$8.355

最低

$7.660

交易量

2.85M

公司基本面

市值

597.8M

行業

生物科技

國家

United States

交易統計

平均交易量

1.04M

交易所

NGM

貨幣

USD

52週範圍

最低 $1.45當前 $8.190最高 $11.72

相關新聞

PR Newswire

Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions

Equity InsiderNews Commentary – Conventional small molecule approaches have struggled to address genetic defects and complex disease mechanisms,...

查看更多
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on Lexeo Therapeutics, Lowers Price Target to $13

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Lexeo Therapeutics with a Buy and lowers the price target from $15 to $13.

查看更多
HC Wainwright & Co. Maintains Buy on Lexeo Therapeutics, Lowers Price Target to $13
Analyst Upgrades

Chardan Capital Maintains Buy on Lexeo Therapeutics, Raises Price Target to $17

Chardan Capital analyst Geulah Livshits maintains Lexeo Therapeutics with a Buy and raises the price target from $15 to $17.

查看更多
Chardan Capital Maintains Buy on Lexeo Therapeutics, Raises Price Target to $17
GlobeNewswire

Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy

U.S. Food and Drug Administration (FDA) open to pooling data from ongoing Phase I/II studies of LX2006 with pivotal data to support a Biologics License Application (BLA) for Accelerated Approval Interim clinical data

查看更多
Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy